Adam Marcus

Apparent duplication from anesthesiology journal puts heart paper into intensive care

A heart journal has issued an expression of concern about a 2017 paper which looks suspiciously like a 2016 article by some of the same researchers that appeared in an anesthesiology publication.

The 2017 paper, “Efficacy of prophylactic dexmedetomidine in preventing postoperative junctional ectopic tachycardia after pediatric cardiac surgery,” was written by a group led by Doaa Mohamed El Amrousy, of Tanta University Hospital in Egypt.

Several months earlier, El Amrousy and two of his co-authors, Nagat S. El-Shmaa and Wael El Feky, published a similar article in the Annals of Cardiac Anesthesia, titled “The efficacy of pre-emptive dexmedetomidine versus amiodarone in preventing postoperative junctional ectopic tachycardia in pediatric cardiac surgery.”

How similar? Apparently too much.

Top chemistry journal retracts paper for faked data

A leading chemistry journal has retracted a 2019 paper by a pair of researchers in Switzerland after determining that it contained fabricated data.

The article, “The manganese(I)‐catalyzed asymmetric transfer hydrogenation of ketones: disclosing the macrocylic privilege,” was written by Alessandro Passera and Antonio Mezzetti, of the ETH Zurich in Switzerland. It appeared in Angewandte Chemie International Edition.

Readers might remember Angewandte Chemie from this post in June about a controversial article it published — and then removed — in the wake of a mass outcry that prompted much of its editorial board to resign and led to the suspension of two of its editors. Fallout from the scandal — in the form of “the journal’s interim Editor-in-Chief Committee” — is evident in the retraction notice, which reads:

Did a journal retract your paper on homeopathy? Meet the journal that will publish your complaint

A homeopathy journal that Elsevier dropped in the wake of concerns about excessive self-citation appears to have carved out a new niche for itself: self-pity.

In 2016, Homeopathy lost its slot on Thomson Reuters’s (now Clarivate’s) influential journal rankings list after an analysis found that more than 70% of citations in the papers it published were of papers it published. That led Elsevier to cut the journal loose — although it remains in business under the umbrella of Thieme, and has since earned its impact factor back. (For more on why that’s important to journals, see this story.)

Part of Homeopathy’s mission under new ownership, it seems, is to criticize journals that have spurned its contributors. Well, one journal, anyway.

Hydroxychloroquine, push-scooters, and COVID-19: A journal gets stung, and swiftly retracts

This may be the scientific publishing version of “the operation was a success, but the patient died.”

The retraction of a Trojan horse paper on the novel coronavirus has called into question the validity of another article in the same journal which found that hydroxychloroquine is effective against Covid-19.

The sting article, “SARS-CoV-2 was Unexpectedly Deadlier than Push-scooters: Could Hydroxychloroquine be the Unique Solution?” — was the brainchild of graduate student Mathieu Rebeaud, aka “Willard Oodendijk” and Florian Cova, of “The Institute for Quick and Dirty Science” (no, not really) in Switzerland. Their goal: to highlight a concerning paper in the Asian Journal of Medicine and Health, which they and others suspect of being a predatory publication — one that is happy to take money to publish anything, while pretending to perform peer review.

Diabetes-COVID-19 paper retracted for lack of ethical approval

An allegation of plagiarism in a paper about Covid-19 in people with diabetes led to a retraction, but not for lifted text.

Earlier this year, the journal Diabetes Technology & Therapeutics, a Mary Ann Liebert title, published “No deleterious effect of lockdown due to COVID-19 pandemic on glycaemic control, measured by glucose monitoring, in adults with type 1 diabetes.” The author was Pilar Isabel Beato-Vi[accent over i]bora, of University Hospital Complex Badajoz, in Spain.

According to the article, the lockdown of Spain in response to the pandemic did not seem to make it harder for people with type 1 diabetes there to control their blood sugar.

The finding made at least one headline, in Medscape, which covered the paper when it appeared online in May.

But it also sounded alarms with at least one reader. As the retraction notice explains:

Paper earns expression of concern after author blames COVID-19 restrictions for not being able to find raw data

The pandemic ate our data.

A group of researchers in India whose findings in a 2015 paper evidently looked too good to be true have received an expression of concern because they claim Covid-19 restrictions have made it impossible to recover their raw data.

The article, “Possible role of P-glycoprotein in the neuroprotective mechanism of berberine in intracerebroventricular streptozotocin-induced cognitive dysfunction,” appeared in Psychopharmacology, a Springer Nature journal. The authors, led by Anil Kumar, were affiliated with the University Institute of Pharmaceutical Sciences at Panjab University in Chandigarh.

Cancer researcher hit with 10-year ban on federal US funding for nearly 100 faked images

A former scientist at Wayne State University in Detroit who lost his PhD from the institution has agreed to a 10-year ban on any federally funded research after being found guilty of misconduct.

The U.S. Office of Research Integrity says Zhiwei Wang fabricated data in nine grants funded by the National Institutes of Health, as well as in three grant applications and his 2006 doctorate.

Wang’s bogus data was published in 15 14 papers, according to the ORI, 14 13 of which already have been retracted. Under the terms of the agreement, Wang will ask for the retraction or correction of the 15th article, a 2008 study in Molecular Cancer Therapeutics titled “Induction of growth arrest and apoptosis in human breast cancer cells by 3,3-diindolylmethane is associated with induction and nuclear localization of p27kip.”

Journal that published paper linking 5G to COVID-19 blames “substantial manipulation of the peer review”

The journal that allowed a bizarre article linking Covid-19 to 5G cell phone waves to “slip through the net” now blames rigged peer review for the fishy paper.

The article, which earned raspberries from the likes of Elisabeth Bik (who called it potentially the “worst” paper of the year) and others, was retracted shortly after publication in the Journal of Biological Regulators and Homeostatic Agents.

As we reported last month, the journal initially simply withdrew the article without explanation. But the publisher, Biolife, then provided us with a few less-than-satisfying excuses, such as:

Study of China’s ethnic minorities retracted as dozens of papers come under scrutiny for ethical violations

A legal journal has retracted a 2019 article on the facial genetics of ethnic minorities in China for ethics violations, and the publisher, Springer Nature, is investigating more than two dozen other articles for similar concerns.

The article, “Y Chromosomal STR haplotypes in Chinese Uyghur, Kazakh and Hui ethnic groups and genetic features of DYS448 null allele and DYS19 duplicated allele,” appeared in the International Journal of Legal Medicine.

Three of the authors were affiliated with the notorious Karamay Municipal Public Security Bureau, which the U.S. government hit with sanctions in October 2019 for being:

Cancer surgery group in China may lose second paper

After whistleblowers in China prompted the retraction of a 2018 paper that overstated the number of patients treated in a study, another journal says it’s investigating a second article by the same group.

Last month, as we reported, the Journal of Surgical Oncology retracted “Long‐term outcomes of 530 esophageal squamous cell carcinoma patients with minimally invasive Ivor Lewis esophagectomy.” The move was prompted by whistleblowers who notified the journal that the 530 cases could not have been performed at the authors’ institution, Zhejiang University, in Hangzhou.

After our post, a Twitter user pointed us to a second article by the group, in BMC Cancer, which claimed to report data on 697 subjects over just one additional year — a highly improbable figure.

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this: